Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
Elias Jabbour(The University of Texas MD Anderson Cancer Center), Andreas Hochhaus(Jena University Hospital), Giuseppe Saglio(University of Turin), M. Brigid Bradley‐Garelik(Bristol-Myers Squibb (United States)), Hesham Mohamed(Bristol-Myers Squibb (United States)), Juan Luis Steegmann(Hospital Universitario de La Princesa), Concepción Boqué(Institut Català d'Oncologia), Michele Baccarani(University of Bologna), Charles Chuah(SingHealth), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Dong‐Wook Kim(The Catholic University of Korea Uijeongbu St. Mary's Hospital), Carolina Pavlovsky(Unknown), Jiří Mayer(Central European Institute of Technology), Mark Wildgust(Bristol-Myers Squibb (United States)), Neil P. Shah(Unknown), Jörge E. Cortes(Augusta University Health)
Cited by 391
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
|Cancer Cell|2002|1.6k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k